Publications by authors named "Zwenger Ariel"
Article Synopsis
- The PI3K/AKT/mTOR pathway is important in the progression and recurrence of breast cancer, with specific mutations and loss of PTEN serving as targets for therapies.
- A study examines phosphorylated ribosomal protein S6 (pS6) as a marker for PI3K pathway activation and its association with recurrence-free survival in early-stage breast cancer patients.
- Findings indicate that a high level of pS6-positive tumor cells correlates with worse prognosis, suggesting it could be a new independent marker for predicting recurrence risk in hormone receptor-positive/HER2-negative breast cancer.
Background: Parathyroid hormone-related peptide (PTHrP) plays a key role in the development and progression of many tumors. We found that in colorectal cancer (CRC) HCT116 cells, the binding of PTHrP to its receptor PTHR type 1 (PTHR1) activates events associated with an aggressive phenotype. In HCT116 cell xenografts, PTHrP modulates the expression of molecular markers linked to tumor progression.
View Article and Find Full Text PDFBackground: Probiotics are used to manage a number of gastrointestinal disorders due to their beneficial properties. Clinical reports showed that probiotics also improve the life quality of patients with colorectal cancer (CRC) subjected to oncologic treatment. In a CRC animal model, probiotics supplementation has the potential to decrease the formation of aberrant crypts and ameliorate tumor malignancy, enhancing the antitumor effect of 5-fluorouracil (5-FU) chemotherapy.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how the pattern of metastatic spread in male breast cancer affects overall survival, as this has been well-established in women but not understood for men.
- Data from the SEER database involving 250 male patients with newly diagnosed metastatic breast cancer between 2010 and 2017 revealed different median overall survival rates based on the metastatic pattern, with bone-only metastases associated with the longest survival.
- The findings indicate that specific factors, such as tumor subtype and the presence of brain metastases, significantly influence survival outcomes, highlighting that brain metastases lead to a significantly poorer prognosis, particularly in younger patients.
Introduction: The world is living through an outbreak of an acute respiratory syndrome caused by a new betacoronavirus known as coronavirus 2 (SARS CoV-2), which has been declared an international public health emergency by the World Health Organisation. Cancer patients are a very special population in this setting since they are more susceptible to viral infections than the general population. Several recommendations have been made on this issue, most of them based on expert opinion and institutional experience.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how different breast cancer tumor subtypes (TS) affect overall survival (OS) across various cancer stages using data from women diagnosed between 2010 and 2013.
- A total of 166,054 patients were analyzed, revealing the distribution of TS, where HR-positive/HER2-negative tumors had the best clinical features but HR-positive/HER2-positive tumors had the highest OS in advanced stages.
- The findings highlight significant differences in OS based on TS in all four stages of breast cancer, with the results confirmed through multivariate analysis, suggesting the need for tailored treatment approaches based on tumor subtype.
Article Synopsis
- The study aimed to compare overall survival (OS) rates between male breast cancer (MBC) and female breast cancer (FBC) patients based on tumor subtype and other factors.
- It analyzed data from 1187 MBC and 166,054 FBC patients, finding that OS at 3 years was 85.6% for MBC and 90.4% for FBC, with MBC patients typically having higher grade and more advanced tumors.
- Results revealed that MBC had worse OS than FBC in early stages and especially in HR+/HER2+ subtypes, indicating men face nearly double the risk of death compared to women with the same tumor type.
Although PTHrP is implicated in several cancers, its role in chemoresistance is not fully elucidated. We found that in CRC cells, PTHrP exerts proliferative and protective effects and induces cell migration. The aim of this work was to further study the effects of PTHrP in CRC cells.
View Article and Find Full Text PDFUnlabelled: Gastric cancer (GC) is the world's second-leading cause of neoplastic mortality. Genetic alterations, response to treatments, and mortality rates are highly heterogeneous across different regions. Within Latin America, GC is the leading cause of cancer death in Chile, affecting 17.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on women diagnosed with brain metastases at the same time as breast cancer, which is a rare and complex situation.
- In the analysis of 740 patients, the median overall survival was found to be 10 months, with only 20.7% surviving at 3 years; tumor subtype significantly influenced survival rates.
- Key findings indicated that triple-negative breast cancer had the shortest median survival of 6 months, while the HR+/HER2+ subtype had the longest, at 22 months; additional factors affecting survival included age, type of tumor histology, presence of liver metastases, and marital status.
Article Synopsis
- Male breast cancer (MaBC) is not well understood, especially regarding the treatment and outcomes for early-stage patients; this study analyzed characteristics, treatments, and survival rates of men with early-stage MaBC.
- The study included 1263 men diagnosed between 1988 and 2012, showing a 5-year overall survival (OS) rate of 85.1%, with older age, higher tumor grades, lack of surgery, and no lymph node examination correlating with poorer outcomes.
- Findings suggest that while men with early MaBC have generally good survival rates, there is a need to reconsider the high rates of mastectomy and extensive lymph node examination since breast conservation and fewer lymph nodes examined yield similar survival rates.
Article Synopsis
- - The study investigates the impact of CD44 and Lewis Y antigen (LeY) on therapy resistance in patients with locally advanced cervical squamous cell carcinoma (LACSCC), showing that these markers relate to tumor behavior and patient outcomes.
- - Data from 126 patients was analyzed, revealing that advanced disease and expression of LeY were linked to poorer survival rates in those treated with standard radiochemotherapy based on cisplatin.
- - While coexpression of CD44 and LeY was not associated with worse outcomes overall, LeY expression specifically indicated shorter disease-free and overall survival in patients receiving radiochemotherapy.
Prognostic factors in male breast cancer: a population-based study.
Breast Cancer Res Treat
April 2016
Article Synopsis
- The study investigated prognostic factors in male breast cancer (MaBC) by analyzing data from 2992 patients diagnosed between 2003 and 2012.
- Results showed that most MaBC cases were ductal, hormone receptor-positive, and early-stage, while grade I tumors were rare.
- Key findings indicated that older age, higher tumor grades, advanced disease stage, lack of surgery or radiotherapy, ER negativity, and being unmarried were linked to shorter overall survival.
During the past years, molecular studies through high-throughput technologies have led to the confirmation of critical alterations in colorectal cancer (CRC) and the discovery of some new ones, including mutations, DNA methylations, and structural chromosomal changes. These genomic alterations might act in concert to dysregulate specific signaling pathways that normally exert their functions on critical cell phenotypes, including the regulation of cellular metabolism, proliferation, differentiation, and survival. Targeted therapy against key components of altered signaling pathways has allowed an improvement in CRC treatment.
View Article and Find Full Text PDFArticle Synopsis
- This study evaluates the roles of ERCC1 and TUBB3 as predictive and prognostic factors in patients with locally advanced cervical squamous cell carcinoma (LACSCC) who are undergoing different chemoradiotherapy regimens.
- High expressions of ERCC1 and TUBB3 were found in a significant portion of patients, with ERCC1 linked to advanced disease stages and poorer survival outcomes in those receiving cisplatin treatment.
- The findings suggest that while ERCC1 expression can indicate patient prognosis, TUBB3 does not influence survival outcomes in patients treated with antimicrotubule therapies.
Article Synopsis
- - The study aims to assess the characteristics and prognostic implications of different tumor subtypes in male breast cancer (MaBC), specifically analyzing data from 960 patients recorded between 2010 and 2012.
- - Patients were categorized into four subtypes based on hormone receptor (HR) and HER2 status, revealing that triple-negative (TN) patients tended to be younger and had poorer outcomes compared to other subtypes.
- - Univariate and multivariate analyses showed that factors like HER2 positivity, tumor stage, and being older significantly impacted overall survival (OS), emphasizing that tumor subtype plays a vital role in prognosis alongside age and stage.
Aim: Colorectal cancer (CRC) is one of the most prevalent malignancies in Argentina with 11,043 new cases and 6,596 deaths estimated to have occurred in 2008. The present study was developed to clarify the differential expression of MUC1, MUC2, sLex, and sLea in colorectal cancer patients and their relationship with survival and clinical and histological features.
Methods: Ninety primary tumor samples and 43 metastatic lymph nodes from CRC patients were studied; follow-up was documented.
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
Breast Cancer Res Treat
January 2014
Article Synopsis
- * After analyzing data from 126 patients over a median follow-up of 4.5 years, the two chemotherapy regimens exhibited similar objective response rates and survival outcomes, with no significant differences in disease-free or overall survival.
- * The study found that the number of pathologically involved lymph nodes was the strongest predictor of survival, and while both regimens were tolerated, CMF had more severe blood-related side effects, while FAC was linked to more hair loss.
Most cases of breast cancer are diagnosed at early stage of disease; therefore, treatment is oriented to increase the disease-free interval (DFI) and overall survival (OS). The prognosis, in comparison with other malignancies, has improved in the last decades as a result of mammographic screening. The aim of the study was to report the incidence of local and distant recurrence, DFI and OS in patients (pts) with stage I and stage II breast cancer over a period of 26 years divided into three groups.
View Article and Find Full Text PDF